Literature DB >> 33501482

QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase.

Borvornwat Toviwek1, Duangkamol Gleeson, M Paul Gleeson.   

Abstract

TAK1 is a serine/threonine kinase which is involved in the moderation of cell survival and death via the TNFα signalling pathway. It is also implicated in a range of cancer and anti-inflammatory diseases. Drug discovery efforts on this target have focused on both traditional reversible ATP-binding site inhibitors and increasingly popular irreversible covalent binding inhibitors. Irreversible inhibitors can offer benefits in terms of potency, selectivity and PK/PD meaning they are increasingly pursued where the strategy exists. TAK1 kinase differs from the better-known kinase EGFR in that the reactive cysteine nucleophile targeted by electrophilic inhibitors is located towards the back of the ATP binding site, not at its mouth. While a wealth of structural and computational effort has been spent exploring EGFR, only limited studies on TAK1 have been reported. In this work we report the first QM/MM study on TAK1 aiming to better understand aspects of covalent adduct formation. Our goal is to identify the general base in the catalytic reaction, whether the process proceeds via a stepwise or concerted pathway, and how the highly flexible G-loop and A-loop affect the catalytic cysteine located nearby.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33501482     DOI: 10.1039/d0ob02273j

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  2 in total

1.  Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study.

Authors:  Ma'mon M Hatmal; Omar Abuyaman; Mutasem Taha
Journal:  Comput Struct Biotechnol J       Date:  2021-08-19       Impact factor: 7.271

2.  Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl s-Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (MDA-MB-231) via EGFR/PI3K/AKT/mTOR Signaling Cascades.

Authors:  Ihab Shawish; Assem Barakat; Ali Aldalbahi; Walhan Alshaer; Fadwa Daoud; Dana A Alqudah; Mazhar Al Zoubi; Ma'mon M Hatmal; Mohamed S Nafie; Matti Haukka; Anamika Sharma; Beatriz G de la Torre; Fernando Albericio; Ayman El-Faham
Journal:  Pharmaceutics       Date:  2022-07-27       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.